Last reviewed · How we verify
Dimethylaminoisopropylazaphenothiazine (ISOTHIPENDYL)
Dimethylaminoisopropylazaphenothiazine (generic name: ISOTHIPENDYL) is a isothipendyl drug. It is currently in Phase 2 development.
Isothipendyl is thought to work by interacting with a specific molecular target, although its exact mechanism of action is not yet fully understood.
Dimethylaminoisopropylazaphenothiazine, also known as isothipendyl, is a small molecule drug of the isothipendyl class. Its mechanism of action and target are currently unknown. Isothipendyl is not FDA-approved for any indications, and its commercial status, patent status, and availability of generic manufacturers are also unknown. Further research is needed to understand its potential therapeutic applications and safety considerations. As a result, key safety considerations and potential side effects are currently undefined.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ISOTHIPENDYL |
|---|---|
| Drug class | isothipendyl |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells have locks on them, and isothipendyl is a key that fits into one of those locks. When it binds to the lock, it can either turn the lock open or closed, depending on the type of lock and the key's shape. This can affect how the cell behaves and responds to signals, but the exact details of how isothipendyl works are still being studied.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dimethylaminoisopropylazaphenothiazine CI brief — competitive landscape report
- Dimethylaminoisopropylazaphenothiazine updates RSS · CI watch RSS
Frequently asked questions about Dimethylaminoisopropylazaphenothiazine
What is Dimethylaminoisopropylazaphenothiazine?
How does Dimethylaminoisopropylazaphenothiazine work?
What is the generic name of Dimethylaminoisopropylazaphenothiazine?
What drug class is Dimethylaminoisopropylazaphenothiazine in?
What development phase is Dimethylaminoisopropylazaphenothiazine in?
Related
- Drug class: All isothipendyl drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing